janssen_latest_logo_on_sign_closer

J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

pharmafile | November 6, 2018 | News story | Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea 

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal worth up to $1.2 billion.

The deal will see J&J pay the South Korean firm $50 million upfront, while the company may pay $1.2 billion in total if commercial and developmental milestones are met. Double digit royalties on sales may also bolster Yuhan’s purse.

The partnership will see Jannsen assume responsibility for the development, manufacture and commercialisation of lazertinib for the treatment of small cell lung cancer (NSCLC) in all global markets outside of South Korea.

Advertisement

Both companies are set to launch global studies looking into the safety and effectiveness of the drug, next year. However Yuhan have already begun studying the drug in South Korea.

Yuhan CEO Lee Jung-hee, commented:“Janssen boasting outstanding expertise in developing anticancer drugs would become our best strategic partner. With the partnership, we will accelerate development of the treatment to improve lives of lung cancer patients.”   

Louis Goss

Related Content

J&J seek approval for first drug to treat high-risk smoldering myeloma

Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …

lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …

The Gateway to Local Adoption Series

Latest content